Detailed explanation of the mechanism of action of Etrasimod

Itramod(Etrasimod) is a new, selective sphingosine-1-phosphate (S1P) receptor modulator, mainly used to regulate the migration of T lymphocytes in the immune system, thereby controlling chronic inflammation in autoimmune-related diseases. As an oral small molecule immunomodulatory drug, Etrasimod is highly selective for the S1P1, S1P4 and S1P5 subtypes of the S1P receptor, but is inactive against S1P2 and S1P3. Therefore, compared with early S1P drugs such as fingolimod, it has better targeting and a lower risk of side effects.

The S1P signaling axis plays an important regulatory role in the circulation of lymphocytes. Expression of the S1P1 receptor becomes a key factor when tissues with high S1P concentrations, such as blood, guide lymphocytes to migrate from lymphoid tissues with low S1P concentrations. Itrimod induces the internalization of S1P1 receptors, causing T cells to be "locked" in lymph nodes and unable to migrate to inflammatory target organs such as the intestinal mucosa. This mechanism is particularly critical in diseases such as ulcerative colitis ( UC), because the aggregation and activation of T cells are the core pathways that cause chronic inflammation and tissue damage in the intestine.

The synergistic effect of S1P4 and S1P5 cannot be ignored. S1P4 is involved in the differentiation of immune cells and the regulation of inflammatory factors, while S1P5 is related to the function of the nervous system and intestinal autonomic nerves. This multi-subtype regulatory mechanism gives itrimod a broader immunomodulatory potential, especially demonstrating differentiated therapeutic advantages in systemic inflammatory diseases or neuroinflammatory diseases.

Compared with traditional immunosuppressants such as glucocorticoids and antimetabolite drugs, itramod does not directly kill or inhibit the function of immune cells, but achieves "directed immune blockade" by blocking their migration pathways. This feature significantly reduces the incidence of side effects such as systemic infection and leukopenia. Preclinical studies have shown that Etrasimod has a controllable onset time and rapid reversal of drug effects, and is the most potentially safe member of the current S1P modulator family.

Reference materials:https://www.drugs.com/mtm/etrasimod.html